CLLS | Cellectis SA
Next ER: May 4, 2023 After Market Closes
About the Company
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris and New York City.
NASDAQ - Nasdaq Stock Market
More profiles and info about the company
News for (CLLS)
This company doesn't provide a dividend.
Talk about Cellectis SA below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
( FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
Support this project
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Currency Trading For Dummies is a hands-on, user-friendly guide that explains how the foreign exchange (ForEx) market works and how you can become a part of it. Currency trading has many benefits, but it also has fast-changing financial-trading avenues. ForEx markets are always moving. So how do you keep up?